

Anticoagulants - Indications, Dosing, Renal Dosing, and Reversal

Medication	Indication	Dose (normal renal function)	Renal Dose Adjustment	Reversal Agent
Enoxaparin (Lovenox)	Treatment of PE/DVT	1mg/kg SQ every 12 hours OR 1.5mg/kg SQ daily	CrCl <30ml/min: 1mg/kg SQ daily	Protamine – Max dose 50mg If <8 hours from dose: 1mg per 1mg of enoxaparin If >8 hours from dose: 0.5mg per 1 mg of enoxaparin ²
Apixaban (Eliquis)	Prevention of stroke in nonvalvular a fib	5mg PO twice daily	2.5mg PO twice daily – if two or more of following: age>80, wt ≤60kg, sCr ≥1.5mg/dL	No approved antidote but may consider: KCentra 50 units/kg IV x 1 for life-threatening/severe bleeding ³
	Treatment of PE/DVT	10mg PO twice daily x 7 days then 5mg PO twice daily	No dose adjustment NOTE: patients with sCr>2.5mg/dL or CrCl<25 ml/min were excluded from trials	
Edoxaban (Savaysa)	Prevention of stroke in nonvalvular a fib	60mg PO daily (Contraindicated in patients with CrCl>95ml/min)	CrCl 15-50 ml/min: 30mg PO daily CrCl<15 ml/min: Not recommended	No approved antidote but may consider: KCentra 50 units/kg IV x1 for life-threatening/severe bleeding ³
	Treatment of PE/DVT	60mg PO daily after 5-10 days of treatment with a parenteral agent If wt≤60kg, 30mg PO daily	CrCl 15-50 ml/min: 30mg PO daily CrCl<15 ml/min: Not recommended	
Rivaroxaban (Xarelto)	Prevention of stroke in nonvalvular a fib	20mg PO daily with evening meal	CrCl 15-50 ml/min :15mg PO with evening meal CrCl<15 ml/min: Not recommended	No approved antidote but may consider: KCentra 50 units/kg IV x1 for life-threatening/severe bleeding ³
	Treatment of PE/DVT	15mg PO twice daily with food x 3 weeks, then 20mg PO daily with food	CrCl <30 ml/min: Avoid use	
Dabigatran (Pradaxa)	Prevention of stroke in nonvalvular a fib	150mg PO twice daily	CrCl 15-30ml/min: 75mg PO twice daily	Idarucizumab (Praxbind) 5gm IV x 1 ³
	Treatment of PE/DVT	150mg PO twice daily after 5-10 days of treatment with parenteral agent	CrCl ≤ 30ml/min:	

References:

1. Lexi-Comp
2. Garcia DA, Baglin TP, Weitz JI et al. Parenteral Anticoagulants. CHEST 2012; 141: 24-43.
3. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care 2016;24: 6-46.